跳至主要内容
临床试验/EUCTR2021-001019-95-IT
EUCTR2021-001019-95-IT进行中(未招募)1 期

Pharmacokinetic/pharmacodynamic aspects of colistin intravenous administration in critically ill patients suffering from hospital infections caused by multi-antibiotic-resistant germs and receiving continuous renal replacement therapy. - COLIMICINA

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 20 人开始时间: 2021年6月8日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • oAge> 18 yy
  • oDuration of treatment planned for at least 48 hours
  • oInfection where the involvement of MDR germs is documented or highly probable
  • oContinuous renal replacement therapy
  • oAcute renal failure, stage III of the 2012 KDIGO classification
  • oHalf-life of the continuous renal replacement therapy filter less than 48 hours.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • oState of pregnancy
  • oRefusal of informed consent
  • oKnown hypersensitivity to polymyxins
  • oClinical condition with high probability of death, according to Symplified Acute Physiology Score (SAPS II)
  • oPartial maintenance of renal function, defined by stages I and II of the 2012 KDIGO classification.
  • oRenal replacement therapy filter other than AN69 ST 150

研究者

发起方
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE

相似试验